anti-inflammatoty and immuno-therapy - versus standard of care - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.10 [0.79, 1.53]< 10%12 studies (12/-)29.5 %some concernlow moderatecrucial-
deaths 0.91 [0.80, 1.03]< 10%24 studies (24/-)93.6 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.87 [0.64, 5.45]< 10%2 studies (2/-)12.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.63 [0.45, 0.88]< 10%4 studies (4/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.67 [1.12, 2.50]> 172%7 studies (7/-)99.4 %some concernserious moderateimportant-
clinical improvement (14-day) 3.46 [0.92, 13.03]> 136%2 studies (2/-)96.6 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.66 [0.75, 3.67]> 164%4 studies (4/-)89.5 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 2.47 [0.37, 16.27]> 172%2 studies (2/-)82.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.83 [1.24, 2.70]> 19%4 studies (4/-)99.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.93 [0.35, 2.49]< 163%2 studies (2/-)55.7 %some concernnot evaluable moderateimportant-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1/-)92.4 %NAnot evaluable important-
mechanical ventilation 0.98 [0.61, 1.57]< 10%7 studies (7/-)53.7 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.66 [0.25, 1.72]< 10%1 study (1/-)80.2 %NAnot evaluable important-
radiologic improvement (14-day) 3.53 [1.19, 10.46]> 10%2 studies (2/-)98.9 %some concernnot evaluable moderateimportant-
viral clearance 6.97 [0.23, 210.35]> 189%2 studies (2/-)86.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 7.68 [0.34, 173.70]> 190%2 studies (2/-)89.7 %some concernnot evaluable moderateimportant-
ICU admission 0.60 [0.36, 0.98]< 10%5 studies (5/-)97.9 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.33 [0.84, 2.10]< 136%6 studies (6/-)11.0 %some concernnot evaluable moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %NAnot evaluable important-
adverse events 1.14 [0.92, 1.43]< 10%4 studies (4/-)11.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.